India and Thailand have taken varied approaches to ensure access to medicines for their populations. Thailand has widened the TRIPS provisions in the application of diseases that are not communicable or life-threatening. India has utilized means other than compulsory licensing to ensure access to drugs. The response by interest groups to these actions is seminal in determining the possible applicability of these choices to ensure local production as well as in consideration of the demand for Tamiflu in countries such as China and India. |